Endo, Vernalis get FDA rejection for Frova
Endo Pharmaceuticals and Vernalis have received a "not approvable" letter for an additional indication for its migraine medicine Frova. The companies had hoped to gain an approval for menstrual migraines, but the FDA called the sNDA weak, and questioned whether trial results were clinically significant for menstrual migraine. "The FDA raised a number of issues that will need to be fully analyzed and then discussed with the FDA. Following this discussion with the FDA, Endo and Vernalis will decide upon the appropriate course of action," stated Peter A. Lankau, Endo President and CEO.
- see the release for more
Related Articles:
Endo plans for the future. Report
Vernalis reports "striking" weight loss in trial. Report
Vernalis acquires Cita, adds drugs to pipeline. Report
Be the first to comment Rate it:
Comments
Post new comment
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends